NEW YORK (GenomeWeb News) — Luminex today said it plans to acquire Canadian molecular diagnostic company Tm Bioscience in a stock-for-stock deal.
 
Luminex said it plans to use what it calls Tm’s “strong menu of kits and reagents” with its own business connections to enhance its sales by getting Tm’s products to wider markets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.